A Phase Ii Trial Of Belotecan In Relapsed Sclc

Y. C. Kim, K. S. Kim, S. Y. Kim,E. T. Jeong,M. H. Jung, K. H. Lee, J. C. Lee,J. S. Ryu, K. O. Park, S. M. Back,I. J. Oh, S. O. Kim, J. P. Jung, J. G. Son, M. R. Kim,K. J. Na, Y. H. Kim,S. J. Ahn

PROCEEDINGS OF THE 10TH CENTRAL EUROPEAN LUNG CANCER CONFERENCE（2006）

引用 0|浏览4

暂无评分

摘要

A phase II trial of belotecan; a novel topoisomerase I inhibitor, was conducted for 42 patients with SCLC relapsed after etoposide and platinum chemotherapy. Response rate to belotecan was 23.8%. Median survival time (MST) from the beginning of belotecan treatment was 8.4 months and median progression free survival was 2.4 months. There were no significant differences in response rate and overall and progression free survival between 18 sensitive relapsed patients and 24 refractory relapsed patients.Compared to previous phase II(1,2) and III(3) trials of topotecan, similar or superior efficacy and survival was observed with lower incidence of adverse reactions. A Phase III randomized multi-center trial is designed to compare belotecan with topotecan in relapsed SCLC after first line treatment.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要